Key facts
- It has raised $8.8M across 4 recorded rounds; the latest was Seed Round ($2.5M) in Jun 2025.
- Notable investors include Canadian Institutes of Health Research, The University of British Columbia, entrepreneurship@UBC.
- BirchBioMed has filed 8 Form Ds with the SEC since 2016, most recently Oct 2025 ($2.5M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for BirchBioMed
Funding rounds
4 roundsAbout BirchBioMed
Operator of a clinical-stage biopharmaceutical company intended to develop treatments for organ fibrosis, scarring, and associated skin disorders, as well as specific subsets of autoimmune disorders. The company focuses on the clinical evaluation, development, and commercialization of anti-scarring drugs, autoimmune therapeutics, and novel strategies for transplantation, enabling healthcare institutions to access drugs for quick healing.
- Sector
- Healthcare
- HQ
- Toronto, Canada
- Founded
- 2014
- Employees
- 6
- Website
- birchbiomed.com/
- Ownership
- Privately Held (backing)
BirchBioMed doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BirchBioMed shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BirchBioMed in its N-PORT filings yet. We sweep new filings monthly.